ALPELISIB

Search structure
Trade Names:
Synonyms:
Status: Approved (2019)
Entry Type: Small molecule
Molecule Category: UNKNOWN
ATC: L01EM03
UNII: 08W5N2C97Q

Structure
InChI Key STUWGJZDJHPWGZ-LBPRGKRZSA-N
Smile Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(C(C)(C)C(F)(F)F)c1
InChI
InChI=1S/C19H22F3N5O2S/c1-10-14(11-6-7-24-13(9-11)18(2,3)19(20,21)22)30-16(25-10)26-17(29)27-8-4-5-12(27)15(23)28/h6-7,9,12H,4-5,8H2,1-3H3,(H2,23,28)(H,25,26,29)/t12-/m0/s1

Physicochemical Descriptors

Property Name Value
Molecular Formula C19H22F3N5O2S
Molecular Weight 441.48
AlogP 3.84
Hydrogen Bond Acceptor 5.0
Hydrogen Bond Donor 2.0
Number of Rotational Bond 4.0
Polar Surface Area 101.21
Molecular species NEUTRAL
Aromatic Rings 2.0
Heavy Atoms 30.0

Pharmacology

Action Mechanism of Action Reference
INHIBITOR PI3-kinase p110-alpha subunit inhibitor PubMed PubMed
Primary Target
phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha
Targets EC50(nM) IC50(nM) Kd(nM) Ki(nM) Inhibition(%)
Enzyme Kinase Protein Kinase Atypical protein kinase group Atypical protein kinase PIKK family Atypical protein kinase FRAP subfamily
- 1461-3000 - - -
Enzyme Transferase
- 5-200 - - -
Enzyme
- 5-200 - - -

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Neoplasms 4 D009369 ClinicalTrials
Breast Neoplasms 4 D001943 FDA
Breast Neoplasms 4 D001943 ClinicalTrials
Ovarian Neoplasms 3 D010051 ClinicalTrials
Squamous Cell Carcinoma of Head and Neck 2 D000077195 ClinicalTrials
Carcinoma, Squamous Cell 2 D002294 ClinicalTrials
Carcinoma, Squamous Cell 2 D002294 ClinicalTrials
Head and Neck Neoplasms 2 D006258 ClinicalTrials
Colorectal Neoplasms 2 D015179 ClinicalTrials
Oropharyngeal Neoplasms 1 D009959 ClinicalTrials
Liver Diseases 1 D008107 ClinicalTrials
Gastrointestinal Stromal Tumors 1 D046152 ClinicalTrials
Meningioma 1 D008579 ClinicalTrials
Esophageal Neoplasms 1 D004938 ClinicalTrials
Pancreatic Neoplasms 1 D010190 ClinicalTrials
Stomach Neoplasms 1 D013274 ClinicalTrials
Multiple Myeloma 1 D009101 ClinicalTrials
Rectal Neoplasms 1 D012004 ClinicalTrials

Adverse Reactions

SOC By Demographic Distribution
System Organ Classification (SOC)
Relative Frequency (%)
General disorders and administration site conditions
13.5
Gastrointestinal disorders
12.0
Investigations
12.0
Metabolism and nutrition disorders
12.0
Skin and subcutaneous tissue disorders
8.0
Endocrine disorders
6.5
Respiratory, thoracic and mediastinal disorders
6.0
Vascular disorders
6.0
Infections and infestations
5.5
Nervous system disorders
4.0
Cardiac disorders
3.0
Musculoskeletal and connective tissue disorders
2.5

Cross References

Resources Reference
CAS NUMBER 1217486-61-7
ChEBI 93752
ChEMBL CHEMBL2396661
DrugBank DB12015
DrugCentral 5328
EPA CompTox DTXSID70153355
FDA SRS 08W5N2C97Q
Guide to Pharmacology 7955
PDB 1LT
PubChem 56649450
SureChEMBL SCHEMBL1911869
ZINC ZINC000068198368
CONTENTS